NASDAQ: MMEDMinimed Group Inc Stock
$17.64-0.03 (-0.17%)
Updated Jul 28, 2026
MMED Price
$17.64
Fair Value Price
N/A
Market Cap
$4.95B
52 Week Low
$10.65
52 Week High
$20.48
P/E
-13.57x
P/B
1.37x
P/S
1.09x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.10B
Earnings
-$333.00M
Gross Margin
54.2%
Operating Margin
-6.61%
Profit Margin
-10.7%
Debt to Equity
0.28
Operating Cash Flow
-$197M
Beta
1.01
Next Earnings
Sep 1, 2026
Ex-Dividend
N/A
Next Dividend
N/A
MMED Overview
MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. The company's diverse portfolio features essential tools like insulin pumps, continuous glucose monitoring (CGM) systems, infusion sets, specialized software platforms, and various supplementary accessories. These innovations are crafted to enable both patients and healthcare providers to accurately monitor and precisely regulate blood glucose levels. The enterprise was established in 1983 by Alfred E. Mann and is currently headquartered in Northridge, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MMED's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
C
MMED
Ranked#29 of 43
Ranked#29 of 43
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $43.05 | A | |
| $6.34 | B | |
| $72.46 | B |
Be the first to know about important MMED news, forecast changes, insider trades & much more!
MMED News
Overview
Due Diligence Score
–
Industry Average (31)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MMED scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MMED is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MMED is good value based on its book value relative to its share price (1.37x), compared to the US Health Information Services industry average (3.42x)
P/B vs Industry Valuation
MMED is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MMED due diligence checks available for Premium users.
Valuation
MMED fair value
Fair Value of MMED stock based on Discounted Cash Flow (DCF)
Price
$17.64
Fair Value
$44.83
Undervalued by
60.65%
MMED is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MMED price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-13.57x
Industry
12.04x
Market
14.6x
MMED price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.37x
Industry
3.42x
MMED is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MMED's financial health
Profit margin
Revenue
$837.0M
Net Income
-$185.0M
Profit Margin
-22.1%
MMED's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MMED's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$4.6B
Liabilities
$1.0B
Debt to equity
0.28
MMED's short-term assets ($1.35B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MMED's short-term assets ($1.35B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MMED's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$170.0M
Investing
-$56.0M
Financing
$512.0M
MMED's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MMED vs Health Information Service Stocks
Minimed Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.